Broad neutralization coverage of HIV by multiple highly potent antibodies - Test2 - elhamkhani - TriplyDB

Broad neutralization coverage of HIV by multiple highly potent antibodies

Broad neutralization coverage of HIV by multiple highly potent antibodies

http://www.wikidata.org/entity/Q29615361

about

HIV-1 superinfection in women broadens and strengthens the neutralizing antibody response Structural mechanism of trimeric HIV-1 envelope glycoprotein activation bNAber: database of broadly neutralizing HIV antibodies A structurally distinct human mycoplasma protein that generically blocks antigen-antibody union Increasing the potency and breadth of an HIV antibody by using structure-based rational design Harnessing the protective potential of HIV-1 neutralizing antibodies Ig Constant Region Effects on Variable Region Structure and Function The HIV glycan shield as a target for broadly neutralizing antibodies Antibody-Based Strategies to Prevent and Treat Influenza Recent strategies targeting HIV glycans in vaccine design Structural insights on the role of antibodies in HIV-1 vaccine and therapy A Blueprint for HIV Vaccine Discovery Designing synthetic vaccines for HIV Antibody responses to envelope glycoproteins in HIV-1 infection HIV-1 neutralizing antibodies: understanding nature's pathways Host-pathogen interaction in HIV infection Antibodies in HIV-1 vaccine development and therapy HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection A global approach to HIV-1 vaccine development Virological features associated with the development of broadly neutralizing antibodies to HIV-1 HIV broadly neutralizing antibody targets Catching HIV 'in the act' with 3D electron microscopy A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen AAV-Delivered Antibody Mediates Significant Protective Effects against SIVmac239 Challenge in the Absence of Neutralizing Activity Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site Antigenic properties of the human immunodeficiency virus envelope glycoprotein gp120 on virions bound to target cells Molecular evolution of broadly neutralizing Llama antibodies to the CD4-binding site of HIV-1 Modeling neutralization kinetics of HIV by broadly neutralizing monoclonal antibodies in genital secretions coating the cervicovaginal mucosa HIV-1 receptor binding site-directed antibodies using a VH1-2 gene segment orthologue are activated by Env trimer immunization Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9 Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield Broad and potent neutralization of HIV-1 by a gp41-specific human antibody

P2860

Q21090490-32D5FBD0-3393-4691-BC66-3D2EFBBA022F Q21131394-3A954B7E-D508-4187-8542-F64DDBFBF578 Q24567758-F0A87815-8009-4BAB-89A8-6A61550A43BA Q24568048-9AC705C0-5473-4614-953D-FF6E21FD96B5 Q24631510-FE86F77C-408A-445B-98A5-ED7096C56D24 Q26766153-127CFA64-3686-4160-9225-E9E32824BD28 Q26766449-0EDAFE15-E390-443F-A3BB-7A06DCD7D9A9 Q26786540-2B8B1325-CC9B-4914-AF9A-DC8D3DB8D0FE Q26798520-94476F5F-A5EA-4391-8E58-6746A307ED7B Q26823603-BBA85C78-F7BA-44FD-BBB7-B3C0E988A75C Q26829461-0DF53F75-1542-4D1B-8115-9C72B1523DB2 Q26829865-765CF047-B56E-4763-A09C-220746E23E42 Q26862617-FDEC51ED-DC5D-4B65-B2E9-504E07F09C21 Q26991572-5CE4CC8F-79CA-4829-93FA-20F94E3683E1 Q27000480-A2D9FEBF-62AF-4C58-ABED-331F89ED3B72 Q27009024-FDF389A6-263B-4BF9-9B45-BB2C540D9E2C Q27011574-299CE6E1-1CC1-4B8F-9D98-2A2F280AF92A Q27022055-5BCE7049-3CAB-4EF3-9B9E-975EDE99BF42 Q27022652-C50CDE4A-64C9-4F6C-A35D-D56406763877 Q27024614-352A6B6D-327E-4643-BCE3-EDCC632EF5B0 Q27025177-344A34E7-123C-4F93-8A64-B1E7EECA00D3 Q27026662-1B493D79-A545-467F-92CB-4A36652C9CEE Q27026806-6F0F37E3-8E85-4AC6-AD33-A863F0C6839F Q27302081-114F7DAD-D644-44B8-B800-648D309D61B6 Q27318266-FC465C6E-2D9E-4B3C-B564-78338A70B9E3 Q27319450-62781F7F-8D07-4FAF-80F1-FE7389B7D1EA Q27320687-F70A2FA8-7A83-41E3-BB40-29D7C848B53F Q27322403-FD50CC5C-6ECA-4560-9C50-119F048E4A3D Q27322437-BF56960F-BDA7-4463-AEA1-3C5FD5B5BF8C Q27324184-97A51160-9736-4332-BE5B-3AE0F03371F6 Q27644383-2B297C21-DE66-47B0-81B3-ADB70912D7D2 Q27644478-A152424B-3D91-4F4D-995D-EF56096D49CF Q27644501-55C192AA-060A-4F20-AF5A-76711DBEF4FC Q27644515-2EC68E2A-91F6-464B-8862-8201D8B23620 Q27644634-74154DBC-7D67-4A10-ADA6-5F7669467AFC Q27644646-1152098C-F3E6-47F6-B49A-E1427936A046 Q27654848-FF67ABEC-ED0F-4ED8-BC87-253C8A3F3B9D Q27674878-E5C3E4E5-BE68-4D09-B13B-D3416EA190EA Q27675032-10099FA8-028D-463D-AA42-A46ACA8FA6BF Q27675131-8EF89EF9-C05F-4B44-8B87-0A0273E6E9A5

P2860

Broad neutralization coverage of HIV by multiple highly potent antibodies

http://www.wikidata.org/entity/Q29615361

description

2011 nî lūn-bûn

@nan

2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Broad neutralization coverage of HIV by multiple highly potent antibodies

@ast

Broad neutralization coverage of HIV by multiple highly potent antibodies

@en

type

label

Broad neutralization coverage of HIV by multiple highly potent antibodies

@ast

Broad neutralization coverage of HIV by multiple highly potent antibodies

@en

prefLabel

Broad neutralization coverage of HIV by multiple highly potent antibodies

@ast

Broad neutralization coverage of HIV by multiple highly potent antibodies

@en

P1433

Q29615361-2509F72F-E534-45B9-8385-FF01D96AEDD9

P1476

Q29615361-366824DD-7524-44F2-AE9A-231DBACB84DA

P2093

Q29615361-02D5AB26-2D25-4A02-B930-6AD6E16954D2

Q29615361-02E81559-18B0-406A-9F73-B2179F5D6AE9

Q29615361-1038FCCB-5ADD-4200-B461-1001A6D6ABAC

Q29615361-2143A3FC-EF3B-415D-B545-06600C6E8357

Q29615361-239F0FD9-3553-43E4-A89A-A82C9F302F01

Q29615361-4AF3D4DF-3646-428E-B976-03CF9D3201DE

Q29615361-553541B7-BCD3-4148-B10F-4C058D491BE7

Q29615361-6726D480-6151-492F-911F-D5BB8CAE04BA

Q29615361-6D8E4EFD-0D40-4844-AAD2-8B76FD867372

Q29615361-760DBCFD-8C38-4D61-9429-E758B43ED601

P2860

Q29615361-05D73AA1-C1AE-4B25-B924-1339A77B2DB9

Q29615361-1F5DDE05-2C7B-4F31-93A7-BDBBF4C3C88B

Q29615361-2802EA79-28EE-4726-A07E-5ACE329E2F52

Q29615361-2E1D6243-B494-42FE-B5AC-6A13EFABE87E

Q29615361-32EF379F-AC9B-408F-BAD1-32636E0B7257

Q29615361-35D2BAE9-2B9E-4D00-9666-5170D90C4AF3

Q29615361-3C4B7812-1A71-4D62-844F-7A9982A78BAC

Q29615361-508EDB15-7321-493A-99C5-098EFDA4A6D0

Q29615361-661A541C-A3B0-4907-9962-F4C8CE858F7F

Q29615361-673F5863-625B-41A5-BAEF-0A228D3D1FA9

P2888

Q29615361-EE539FB9-ED64-4F29-A4E0-83FFF1F599D7

P304

Q29615361-C5FE313B-82EE-41AA-B834-12CCA72873D0

P31

Q29615361-6F3285AF-1690-49DB-8DA9-4F87F92845D1

P3181

Q29615361-3F20B6D0-D4F0-4C3F-A5FE-B2447586CA4A

P356

Q29615361-89B6F06D-A010-433B-B09A-D7C9AAAEB857

P407

Q29615361-C6AB4DC8-F2FA-41C4-A427-4012048B321B

P433

Q29615361-D58B7FAA-4C11-4DE8-A6C1-91731D7D27A1

P478

Q29615361-598290AA-348E-4954-8431-BDFB83CCFDD0

P50

Q29615361-2D5DB46E-A73C-4B54-B91C-B45EF3289533

Q29615361-915094D5-8912-45C4-9175-90C06635E25B

Q29615361-F61AD370-58CF-4DBD-AB0E-27DBAE75C156

P577

Q29615361-08A9EBFA-A20B-41DE-9397-9388A69AEEAE

P5875

Q29615361-0865551E-DEBB-41AB-BE11-AAE86AB6D7E2

P6179

Q29615361-59160B4B-BFED-47AA-89F2-BA0A84DF38EA

P698

Q29615361-A846A0CD-C46E-4061-ACF2-C6603F5BBE3F

P921

Q29615361-7A6DF48E-BC35-4B48-A6E9-4B48EFB73099

Q29615361-81beff5f-4a66-a04d-1e11-ec4b8a3d3e90

P932

Q29615361-663A6640-02F3-40A0-94D7-99F871A8F64B

P3181

P356

P1433

P1476

Broad neutralization coverage of HIV by multiple highly potent antibodies

@en

P2093

Alejandra Ramos

http://www.w3.org/2001/XMLSchema#string

Chi-Huey Wong

http://www.w3.org/2001/XMLSchema#string

Dennis R Burton

http://www.w3.org/2001/XMLSchema#string

Emilia Falkowska

http://www.w3.org/2001/XMLSchema#string

Ian A Wilson

http://www.w3.org/2001/XMLSchema#string

Jennifer L Mitcham

http://www.w3.org/2001/XMLSchema#string

Laura M Walker

http://www.w3.org/2001/XMLSchema#string

Matthew Moyle

http://www.w3.org/2001/XMLSchema#string

Melissa D Simek

http://www.w3.org/2001/XMLSchema#string

Ole A Olsen

http://www.w3.org/2001/XMLSchema#string

P2860

Printed covalent glycan array for ligand profiling of diverse glycan binding proteins

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis

Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120.

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

Rapid evolution of the neutralizing antibody response to HIV type 1 infection

Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1

The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus.

P2888

P304

466-470

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

190580

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NATURE10373

http://www.w3.org/2001/XMLSchema#string

P407

P433

7365

http://www.w3.org/2001/XMLSchema#string

P478

477

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Philippe Julien

P577

2011-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51579243

http://www.w3.org/2001/XMLSchema#string

P6179

1044845665

http://www.w3.org/2001/XMLSchema#string

P698

21849977

http://www.w3.org/2001/XMLSchema#string

P921

P932

3393110

http://www.w3.org/2001/XMLSchema#string